Compounds > nq301
Page last updated: 2024-12-09

nq301

Description

NQ301: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID781109
CHEMBL ID3322530
SCHEMBL ID6506775
MeSH IDM0362213

Synonyms (31)

Synonym
CBMICRO_013906
BIM-0014046.P001
AKOS001487791
2-(4-acetylanilino)-3-chloronaphthalene-1,4-dione
smsf0004585
CB08790
AB00075438-02
AB00075438-01
CHEMBL3322530 ,
2-[(4-acetylphenyl)amino]-3-chloronaphthalene-1,4-dione
STL421257
nq301
130089-98-4
SCHEMBL6506775
2-(4-acetylphenylamino)-3-chloronaphthalene-1,4-dione
CS-6193
HY-101054
2-[(4-acetylphenyl)amino]-3-chloro-1,4-dihydronaphthalene-1,4-dione
EX-A1233
sr-01000198770
SR-01000198770-1
nq301, >=98% (hplc)
2-[(4-acetylphenyl)amino]-3-chloro-1,4-naphthalenedione
nq 301
2-((4-acetylphenyl)amino)-3-chloronaphthalene-1,4-dione
BCP24908
nq-301
BS-14839
D84051
bdbm50594492
AC-36839
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)IC50 (µMol)0.29000.29002.20754.2300AID1870724
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
MAPK cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
hematopoietic progenitor cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of humoral immune response mediated by circulating immunoglobulinTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
G protein-coupled receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of angiogenesisTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
platelet formationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell costimulationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of mast cell activation involved in immune responseTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
megakaryocyte developmentTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of T cell proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
natural killer cell mediated cytotoxicityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of apoptotic processTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of MAPK cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of B cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
platelet aggregationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of inflammatory response to woundingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
epididymis developmentTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycleTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
intracellular signal transductionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
mitotic cell cycleTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
phosphotyrosine residue bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
transmembrane receptor protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
SH2 domain bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell adhesion molecule bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
phosphorylation-dependent protein bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
extracellular regionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleolusTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell-cell junctionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
membraneTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
specific granule lumenTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
extracellular exosomeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
tertiary granule lumenTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
alpha-beta T cell receptor complexTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1183563Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives.
AID1183566Cytotoxicity against human MOLT3 cells after 48 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives.
AID1183571Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human MOLT3 cells2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives.
AID1183564Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives.
AID1183569Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human HuCCa1 cells2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives.
AID1870724Inhibition of human SHP1
AID1183565Cytotoxicity against human A549 cells after 48 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives.
AID1183570Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human A549 cells2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives.
AID1183568Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human HepG2 cells2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives.
AID1183567Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.76 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dichlone
dichlone: structure		2.110
etoposide
[no description available]		2.110beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
arachidonic acid
icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.		2.0210icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
prostaglandin d2
Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).		2.0210prostaglandins Dhuman metabolite;
mouse metabolite
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		2.730
thromboxane b2
Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.		2.0210thromboxanes Bhuman metabolite;
mouse metabolite
12-hydroxy-5,8,10,14-eicosatetraenoic acid
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid: A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51)		2.0210
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid: A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Clot
[description not available]		0210
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		0210
chemdatabank.com